Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a haematological malignancy representing the most diagnosed non-Hodgkin's lymphoma (NHL) subtype. Despite the approved chemotherapies available in clinics, some patients still suffer from side effects and relapsed disease. Recently, studies have reported...
Saved in:
Main Authors: | Sicong Wang (Author), Erin Clapper (Author), Kathryn F. Tonissen (Author), Giovanna Di Trapani (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expanding the armory for treating lymphoma: Targeting redox cellular status through thioredoxin reductase inhibition
by: Sicong Wang, et al.
Published: (2022) -
SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer
by: Yunlong Lu, et al.
Published: (2023) -
Changes of 8-OHdG and TrxR in the Residents Who Bathe in Radon Hot Springs
by: Gao Yanxiao, et al.
Published: (2019) -
Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020) -
Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
by: Qianqian Zhang, et al.
Published: (2019)